Janus kinase inhibitors and their use in non-infectious orbital inflammatory disorders: new treatment possibilities? A case series.

We present a patient with isolated autoimmune anterior scleritis and a patient with nonspecific orbital inflammation (NSOI). Both patients were treated with systemic corticosteroids during multiple recurrences, with the addition of various disease-modifying antirheumatic drugs (DMARDs), including biologics, in the case of scleritis, resulting in complications and local adverse events. Both patients were subsequently effectively managed using Janus kinase inhibitors (JAK-i), specifically baricitinib and tofacitinib without relapses of inflammation during the follow-up of more than one year. Only a slight transient increase in liver enzymes was reported in a patient with scleritis and no serious side effects. [ABSTRACT FROM AUTHOR]